simplywall.st Earnings
News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 1–36
- Matches
- 366
- Sources here
- 20
- Companies here
- 12
Active search
366 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
How Stronger Q2 Results and Capital Moves Could Reshape Genesis Energy’s (GEL) Investment Profile
Genesis Energy (GEL) reported stronger Q2 2026 results with increased revenue and net income, along with the completion of a share repurchase program. The company is also focusing on reducing high-cost preferred equity and exploring refinancing options, which could de-risk its capital structure. Despite …
Price to sales forward of Bridgeline Digital, Inc. – BX:BL43
This article provides the "Price to sales forward" financial metric for Bridgeline Digital, Inc. (BX:BL43). It is presented within the context of TradingView's platform, offering financial data and tools for market analysis. The content primarily focuses on the specific financial metric for the company …
5 Insightful Analyst Questions From Genesis Energy’s Q2 Earnings Call
5 Insightful Analyst Questions From Genesis Energy's Q2 Earnings Call Genesis Energy delivered a strong Q2, with revenue and profit significantly outpacing Wall Street expectations. Management attributed these results to a combination of successful asset sales, cost-saving initiatives, and opportunistic margin gains from temporary …
(RIGL) Price Dynamics and Execution-Aware Positioning
This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) focusing on its price dynamics and execution-aware positioning based on AI models. It identifies strong near and mid-term sentiment, compelling upside potential due to a lack of resistance levels above the current price, and outlines specific …
Aspen Aerogels (NYSE:ASPN) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen has downgraded Aspen Aerogels (NYSE:ASPN) from "Hold" to "Sell," despite some analysts maintaining "Buy" ratings and the company exceeding revenue estimates in its latest earnings report. The stock's average rating is now "Hold" with a price target of $5.94, and it …
Angel Studios CEO Neal Harmon buys $125k in company stock
Angel Studios CEO Neal Harmon recently purchased over $125,000 worth of company stock, acquiring 29,035.659 shares at an average price of $4.3053. This purchase comes as the stock has seen a 34% gain over the last six months despite a 66% decline over the …
NexGel (NXGL) plans big share authorization boost and reverse split to protect Nasdaq listing
NexGel, Inc. (NXGL) is seeking stockholder approval for two major proposals: increasing authorized common stock from 25 million to up to 150 million shares and implementing a discretionary reverse stock split with a ratio between 1-for-2 and 1-for-20. These actions are intended to ensure …
Global X Management (GEL) reports 6.32% beneficial stake in Genesis Energy units
Global X Management Company LLC has reported a beneficial ownership of 7,722,608 common units in Genesis Energy, L.P., which constitutes a 6.32% stake. This ownership is managed through its role as an investment adviser to the Global X MLP ETF. The acquisition was part …
Angel Studios (ANGX) CEO Neal Harmon purchases 29K shares in open-market trade
Angel Studios CEO Neal Harmon purchased 29,035.659 shares of Class A Common Stock on August 13, 2026, in an open-market transaction. The shares were bought at a weighted average price of $4.3053, with individual trades ranging from $4.2650 to $4.3400 per share. Following this …
Bridgeline Digital Ties Record New Customer Wins as AI Search Demand Accelerates
Bridgeline Digital reported strong fiscal third-quarter 2026 results, tying a company record with nine new customer wins and expanding relationships with ten existing accounts, driven by accelerating demand for its AI-powered HawkSearch platform. Core product revenue grew 13% on a trailing twelve-month basis, now …
Armistice Capital (RIGL) reports 1.67M Rigel Pharmaceuticals shares in 13G/A
Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 1,672,000 shares of Rigel Pharmaceuticals (RIGL) common stock through a Schedule 13G/A filing. This represents 8.95% of the outstanding common stock as of June 30, 2026. The shares are held by Armistice Capital …
RIGL Maintained by HC Wainwright & Co. -- Price Target Raised to $85
HC Wainwright & Co. maintained a "Buy" rating for Rigel Pharmaceuticals (RIGL), increasing its price target from $57.00 to $85.00, reflecting confidence in the company's future growth. Despite this, Rigel Pharmaceuticals is currently priced at $42.10, which is 56.7% overvalued compared to its GF …
NEXGEL, Inc. (NASDAQ:NXGL): Are Analysts Optimistic?
NEXGEL, Inc. is nearing profitability, with analysts projecting the company to break even and generate US$3.9 million in profits by 2027, following a US$3.2 million loss in the last twelve months. This forecast implies a significant annual growth rate of 50%. The company's relatively …
Sol-Gel Technologies (SLGL) Projected to Announce Quarterly Earnings on Friday
Sol-Gel Technologies (SLGL) is expected to announce its Q2 2026 earnings before market open on Friday, August 21st, with analysts projecting a loss of $2.36 per share and revenue of $0.0750 million. This follows a previous quarter where the company reported a smaller loss …
Bridgeline Digital Q3 Results: Core Revenue Up 13%, Loss Narrows
Bridgeline Digital (NASDAQ: BLIN) reported Q3 FY26 results, missing analyst expectations with a loss of $(0.04) per share against an estimated $(0.01) and revenue of $3.922 million against a $4.700 million target. Despite the overall revenue miss, core product revenue, primarily driven by AI-powered …
Earnings call transcript: Bridgeline Digital Q3 2026 revenue miss weighs on shares
Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026, at 4:30 p.m. ET CALL PARTICIPANTS Chief Financial Officer-Thomas Windhausen President and Chief Executive Officer-Ari Kahn Full Conference Call Transcript Operator: Good afternoon, and welcome to Bridgeline Digital's Third Quarter 2026 Earnings Call. Please …
Bridgeline Digital (BLIN) Stock Falls on Q3 2026 Earnings
Bridgeline Digital (BLIN) reported Q3 2026 revenue of $3.9 million, missing Wall Street expectations of $4.8 million, and a net loss of $468,000. Following the announcement, the stock fell by 6.19%. Insider trading data shows recent purchases by company executives, while institutional investors largely …
Needham group (ASPN) discloses 3.26M Aspen Aerogels shares with shared voting power
Needham Investment Management L.L.C., Needham Asset Management, LLC, and George A. Needham have filed an amended Schedule 13G disclosing beneficial ownership of 3,260,800 shares of Aspen Aerogels Inc. (ASPN), representing 3.9% of the outstanding common stock. All reported shares are held with shared voting …
Bridgeline Digital, Inc. 2026: Revenue $3.92M, EPS ($0.04) — 10-Q Summary
Bridgeline Digital, Inc. reported its 2026 quarterly results, showing a 2% revenue increase to $3.92M and a narrowed net loss of ($468K), improving EPS to ($0.04). Subscription revenue, particularly from HawkSearch, was the main growth driver, offsetting declines in legacy products. The company also …
Bridgeline Digital (BLIN) narrows loss on $11.8M revenue and low debt
Bridgeline Digital (BLIN) reported total net revenue of $11.8 million for the nine months ended June 30, 2026, a modest increase from the prior year. The company narrowed its nine-month net loss to $1.0 million, compared to $2.2 million a year earlier, with Adjusted …
Bridgeline Announces Financial Results for the Third Quarter of Fiscal 2026
Bridgeline Digital, Inc. announced its financial results for the third quarter of fiscal year 2026, ending June 30, 2026, highlighting record new logo sales and 13% core product revenue growth in the trailing 12 months. Total revenue for the quarter was $3.9 million, with …
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Rigel Pharmaceuticals has announced the commercial availability of VEPPANU (vepdegestrant) in the United States. This drug is the first and only FDA-approved PROTAC and is indicated for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer who have progressed after at least one line …